AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Protein fantom

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q68CZ1

UPID:

FTM_HUMAN

Alternative names:

Nephrocystin-8; RPGR-interacting protein 1-like protein

Alternative UPACC:

Q68CZ1; A0PJ88; Q9Y2K8

Background:

Protein fantom, also known as Nephrocystin-8 and RPGR-interacting protein 1-like protein, plays a crucial role in various cellular processes. It negatively regulates signaling through the G-protein coupled thromboxane A2 receptor and is involved in programmed cell death, craniofacial development, limb patterning, and the formation of the left-right axis. Additionally, it contributes to the organization of apical junctions and the establishment of planar cell polarity, such as in the cochlear sensory epithelium.

Therapeutic significance:

Protein fantom is implicated in several genetic disorders, including Joubert syndrome 7, Meckel syndrome 5, and COACH syndrome 3, all of which involve developmental and structural anomalies. Understanding the role of Protein fantom could open doors to potential therapeutic strategies for these complex conditions, highlighting its significance in medical research and drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.